470 related articles for article (PubMed ID: 35738906)
21. Is
Seifert R; Telli T; Hadaschik B; Fendler WP; Kuo PH; Herrmann K
J Nucl Med; 2023 May; 64(5):731-737. PubMed ID: 36522186
[No Abstract] [Full Text] [Related]
22. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
[TBL] [Abstract][Full Text] [Related]
23. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
[TBL] [Abstract][Full Text] [Related]
24. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
25. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
26. Clinical Experience with [
Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
[TBL] [Abstract][Full Text] [Related]
27. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
28. SUV
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
[TBL] [Abstract][Full Text] [Related]
29. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
[TBL] [Abstract][Full Text] [Related]
30.
Shagera QA; Artigas C; Karfis I; Critchi G; Chanza NM; Sideris S; Peltier A; Paesmans M; Gil T; Flamen P
J Nucl Med; 2022 Aug; 63(8):1191-1198. PubMed ID: 34772793
[TBL] [Abstract][Full Text] [Related]
31. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
32. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. [
Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
[TBL] [Abstract][Full Text] [Related]
35. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
36. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
37. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
38. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Shagera QA; Karfis I; Sideris S; Guiot T; Woff E; Martinez-Chanza N; Roumeguere T; Gil T; Flamen P; Artigas C
Clin Nucl Med; 2023 Sep; 48(9):775-780. PubMed ID: 37385221
[TBL] [Abstract][Full Text] [Related]
39. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [
Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J
J Nucl Med; 2023 Jul; 64(7):1024-1029. PubMed ID: 36997329
[TBL] [Abstract][Full Text] [Related]
40. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]